panel a Search Results


proteome profiler mouse cytokine array kit  (R&D Systems)
98
R&D Systems proteome profiler mouse cytokine array kit
Proteome Profiler Mouse Cytokine Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proteome profiler mouse cytokine array kit/product/R&D Systems
Average 98 stars, based on 1 article reviews
proteome profiler mouse cytokine array kit - by Bioz Stars, 2026-03
98/100 stars
  Buy from Supplier
human cytokine panel  (R&D Systems)
93
R&D Systems human cytokine panel
A . Study design of the 50-gene signature and <t>cytokine</t> analysis in COVID-19 patients (Cohort 1). B. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS. Every column represents a patient, and every row represents a gene. Log-based two-color scale is adjacent to the heatmap. Red denotes increased expression and green denotes decreased expression. Gene expression data is represented as Log2 normalized expression values. C-D. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19, respectively. E-H. Plasma cytokine <t>concentrations</t> <t>(IL6,</t> IP-10, SPP1 and TGFβ) in low, intermediate, and high-risk profile patients with COVID-19 at days 2, 6 and 13 post admission. The data is presented as an average of triplicate values ± SEM for each group. Two-way ANOVA test (GraphPad software) Tukey’s multiple comparisons were used; * p<0.05. I. Study design of 7-gene signature analysis by RT-qPCR in PBMCs from COVID-19 patients (Cohort 2). J. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS Up scores. Heatmap nomenclature is the same as in . K-L. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19 respectively in cohort two. The data is presented as an average of triplicated TUs values ± SEM for each group. * p<0.05
Human Cytokine Panel, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cytokine panel/product/R&D Systems
Average 93 stars, based on 1 article reviews
human cytokine panel - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
resource source identifier critical  (R&D Systems)
97
R&D Systems resource source identifier critical
A . Study design of the 50-gene signature and <t>cytokine</t> analysis in COVID-19 patients (Cohort 1). B. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS. Every column represents a patient, and every row represents a gene. Log-based two-color scale is adjacent to the heatmap. Red denotes increased expression and green denotes decreased expression. Gene expression data is represented as Log2 normalized expression values. C-D. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19, respectively. E-H. Plasma cytokine <t>concentrations</t> <t>(IL6,</t> IP-10, SPP1 and TGFβ) in low, intermediate, and high-risk profile patients with COVID-19 at days 2, 6 and 13 post admission. The data is presented as an average of triplicate values ± SEM for each group. Two-way ANOVA test (GraphPad software) Tukey’s multiple comparisons were used; * p<0.05. I. Study design of 7-gene signature analysis by RT-qPCR in PBMCs from COVID-19 patients (Cohort 2). J. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS Up scores. Heatmap nomenclature is the same as in . K-L. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19 respectively in cohort two. The data is presented as an average of triplicated TUs values ± SEM for each group. * p<0.05
Resource Source Identifier Critical, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/resource source identifier critical/product/R&D Systems
Average 97 stars, based on 1 article reviews
resource source identifier critical - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier
rat proteome profiler cytokine array kit  (R&D Systems)
94
R&D Systems rat proteome profiler cytokine array kit
A . Study design of the 50-gene signature and <t>cytokine</t> analysis in COVID-19 patients (Cohort 1). B. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS. Every column represents a patient, and every row represents a gene. Log-based two-color scale is adjacent to the heatmap. Red denotes increased expression and green denotes decreased expression. Gene expression data is represented as Log2 normalized expression values. C-D. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19, respectively. E-H. Plasma cytokine <t>concentrations</t> <t>(IL6,</t> IP-10, SPP1 and TGFβ) in low, intermediate, and high-risk profile patients with COVID-19 at days 2, 6 and 13 post admission. The data is presented as an average of triplicate values ± SEM for each group. Two-way ANOVA test (GraphPad software) Tukey’s multiple comparisons were used; * p<0.05. I. Study design of 7-gene signature analysis by RT-qPCR in PBMCs from COVID-19 patients (Cohort 2). J. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS Up scores. Heatmap nomenclature is the same as in . K-L. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19 respectively in cohort two. The data is presented as an average of triplicated TUs values ± SEM for each group. * p<0.05
Rat Proteome Profiler Cytokine Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rat proteome profiler cytokine array kit/product/R&D Systems
Average 94 stars, based on 1 article reviews
rat proteome profiler cytokine array kit - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
human cytokine array panel a  (R&D Systems)
94
R&D Systems human cytokine array panel a
A . Study design of the 50-gene signature and <t>cytokine</t> analysis in COVID-19 patients (Cohort 1). B. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS. Every column represents a patient, and every row represents a gene. Log-based two-color scale is adjacent to the heatmap. Red denotes increased expression and green denotes decreased expression. Gene expression data is represented as Log2 normalized expression values. C-D. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19, respectively. E-H. Plasma cytokine <t>concentrations</t> <t>(IL6,</t> IP-10, SPP1 and TGFβ) in low, intermediate, and high-risk profile patients with COVID-19 at days 2, 6 and 13 post admission. The data is presented as an average of triplicate values ± SEM for each group. Two-way ANOVA test (GraphPad software) Tukey’s multiple comparisons were used; * p<0.05. I. Study design of 7-gene signature analysis by RT-qPCR in PBMCs from COVID-19 patients (Cohort 2). J. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS Up scores. Heatmap nomenclature is the same as in . K-L. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19 respectively in cohort two. The data is presented as an average of triplicated TUs values ± SEM for each group. * p<0.05
Human Cytokine Array Panel A, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cytokine array panel a/product/R&D Systems
Average 94 stars, based on 1 article reviews
human cytokine array panel a - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
proteome profiler array  (R&D Systems)
95
R&D Systems proteome profiler array
A . Study design of the 50-gene signature and <t>cytokine</t> analysis in COVID-19 patients (Cohort 1). B. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS. Every column represents a patient, and every row represents a gene. Log-based two-color scale is adjacent to the heatmap. Red denotes increased expression and green denotes decreased expression. Gene expression data is represented as Log2 normalized expression values. C-D. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19, respectively. E-H. Plasma cytokine <t>concentrations</t> <t>(IL6,</t> IP-10, SPP1 and TGFβ) in low, intermediate, and high-risk profile patients with COVID-19 at days 2, 6 and 13 post admission. The data is presented as an average of triplicate values ± SEM for each group. Two-way ANOVA test (GraphPad software) Tukey’s multiple comparisons were used; * p<0.05. I. Study design of 7-gene signature analysis by RT-qPCR in PBMCs from COVID-19 patients (Cohort 2). J. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS Up scores. Heatmap nomenclature is the same as in . K-L. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19 respectively in cohort two. The data is presented as an average of triplicated TUs values ± SEM for each group. * p<0.05
Proteome Profiler Array, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proteome profiler array/product/R&D Systems
Average 95 stars, based on 1 article reviews
proteome profiler array - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
human high sensitivity cytokine kits  (R&D Systems)
94
R&D Systems human high sensitivity cytokine kits
A . Study design of the 50-gene signature and <t>cytokine</t> analysis in COVID-19 patients (Cohort 1). B. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS. Every column represents a patient, and every row represents a gene. Log-based two-color scale is adjacent to the heatmap. Red denotes increased expression and green denotes decreased expression. Gene expression data is represented as Log2 normalized expression values. C-D. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19, respectively. E-H. Plasma cytokine <t>concentrations</t> <t>(IL6,</t> IP-10, SPP1 and TGFβ) in low, intermediate, and high-risk profile patients with COVID-19 at days 2, 6 and 13 post admission. The data is presented as an average of triplicate values ± SEM for each group. Two-way ANOVA test (GraphPad software) Tukey’s multiple comparisons were used; * p<0.05. I. Study design of 7-gene signature analysis by RT-qPCR in PBMCs from COVID-19 patients (Cohort 2). J. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS Up scores. Heatmap nomenclature is the same as in . K-L. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19 respectively in cohort two. The data is presented as an average of triplicated TUs values ± SEM for each group. * p<0.05
Human High Sensitivity Cytokine Kits, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human high sensitivity cytokine kits/product/R&D Systems
Average 94 stars, based on 1 article reviews
human high sensitivity cytokine kits - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
human high sensitivity cytokine  (R&D Systems)
93
R&D Systems human high sensitivity cytokine
A . Study design of the 50-gene signature and <t>cytokine</t> analysis in COVID-19 patients (Cohort 1). B. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS. Every column represents a patient, and every row represents a gene. Log-based two-color scale is adjacent to the heatmap. Red denotes increased expression and green denotes decreased expression. Gene expression data is represented as Log2 normalized expression values. C-D. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19, respectively. E-H. Plasma cytokine <t>concentrations</t> <t>(IL6,</t> IP-10, SPP1 and TGFβ) in low, intermediate, and high-risk profile patients with COVID-19 at days 2, 6 and 13 post admission. The data is presented as an average of triplicate values ± SEM for each group. Two-way ANOVA test (GraphPad software) Tukey’s multiple comparisons were used; * p<0.05. I. Study design of 7-gene signature analysis by RT-qPCR in PBMCs from COVID-19 patients (Cohort 2). J. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS Up scores. Heatmap nomenclature is the same as in . K-L. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19 respectively in cohort two. The data is presented as an average of triplicated TUs values ± SEM for each group. * p<0.05
Human High Sensitivity Cytokine, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human high sensitivity cytokine/product/R&D Systems
Average 93 stars, based on 1 article reviews
human high sensitivity cytokine - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
human biomarker custom premix kit  (R&D Systems)
86
R&D Systems human biomarker custom premix kit
A . Study design of the 50-gene signature and <t>cytokine</t> analysis in COVID-19 patients (Cohort 1). B. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS. Every column represents a patient, and every row represents a gene. Log-based two-color scale is adjacent to the heatmap. Red denotes increased expression and green denotes decreased expression. Gene expression data is represented as Log2 normalized expression values. C-D. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19, respectively. E-H. Plasma cytokine <t>concentrations</t> <t>(IL6,</t> IP-10, SPP1 and TGFβ) in low, intermediate, and high-risk profile patients with COVID-19 at days 2, 6 and 13 post admission. The data is presented as an average of triplicate values ± SEM for each group. Two-way ANOVA test (GraphPad software) Tukey’s multiple comparisons were used; * p<0.05. I. Study design of 7-gene signature analysis by RT-qPCR in PBMCs from COVID-19 patients (Cohort 2). J. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS Up scores. Heatmap nomenclature is the same as in . K-L. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19 respectively in cohort two. The data is presented as an average of triplicated TUs values ± SEM for each group. * p<0.05
Human Biomarker Custom Premix Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human biomarker custom premix kit/product/R&D Systems
Average 86 stars, based on 1 article reviews
human biomarker custom premix kit - by Bioz Stars, 2026-03
86/100 stars
  Buy from Supplier
panel a  (Momenta Pharma)
90
Momenta Pharma panel a
A . Study design of the 50-gene signature and <t>cytokine</t> analysis in COVID-19 patients (Cohort 1). B. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS. Every column represents a patient, and every row represents a gene. Log-based two-color scale is adjacent to the heatmap. Red denotes increased expression and green denotes decreased expression. Gene expression data is represented as Log2 normalized expression values. C-D. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19, respectively. E-H. Plasma cytokine <t>concentrations</t> <t>(IL6,</t> IP-10, SPP1 and TGFβ) in low, intermediate, and high-risk profile patients with COVID-19 at days 2, 6 and 13 post admission. The data is presented as an average of triplicate values ± SEM for each group. Two-way ANOVA test (GraphPad software) Tukey’s multiple comparisons were used; * p<0.05. I. Study design of 7-gene signature analysis by RT-qPCR in PBMCs from COVID-19 patients (Cohort 2). J. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS Up scores. Heatmap nomenclature is the same as in . K-L. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19 respectively in cohort two. The data is presented as an average of triplicated TUs values ± SEM for each group. * p<0.05
Panel A, supplied by Momenta Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/panel a/product/Momenta Pharma
Average 90 stars, based on 1 article reviews
panel a - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
custom milliplex® human cytokine/chemokine/growth factor panel a - immunology multiplex assay  (Burlington Industries)
90
Burlington Industries custom milliplex® human cytokine/chemokine/growth factor panel a - immunology multiplex assay
A . Study design of the 50-gene signature and <t>cytokine</t> analysis in COVID-19 patients (Cohort 1). B. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS. Every column represents a patient, and every row represents a gene. Log-based two-color scale is adjacent to the heatmap. Red denotes increased expression and green denotes decreased expression. Gene expression data is represented as Log2 normalized expression values. C-D. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19, respectively. E-H. Plasma cytokine <t>concentrations</t> <t>(IL6,</t> IP-10, SPP1 and TGFβ) in low, intermediate, and high-risk profile patients with COVID-19 at days 2, 6 and 13 post admission. The data is presented as an average of triplicate values ± SEM for each group. Two-way ANOVA test (GraphPad software) Tukey’s multiple comparisons were used; * p<0.05. I. Study design of 7-gene signature analysis by RT-qPCR in PBMCs from COVID-19 patients (Cohort 2). J. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS Up scores. Heatmap nomenclature is the same as in . K-L. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19 respectively in cohort two. The data is presented as an average of triplicated TUs values ± SEM for each group. * p<0.05
Custom Milliplex® Human Cytokine/Chemokine/Growth Factor Panel A Immunology Multiplex Assay, supplied by Burlington Industries, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/custom milliplex® human cytokine/chemokine/growth factor panel a - immunology multiplex assay/product/Burlington Industries
Average 90 stars, based on 1 article reviews
custom milliplex® human cytokine/chemokine/growth factor panel a - immunology multiplex assay - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human/cytokine/chemokine/growth factor panel a 48-plex premixed magnetic bead multiplex assay  (Merck KGaA)
90
Merck KGaA human/cytokine/chemokine/growth factor panel a 48-plex premixed magnetic bead multiplex assay
A . Study design of the 50-gene signature and <t>cytokine</t> analysis in COVID-19 patients (Cohort 1). B. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS. Every column represents a patient, and every row represents a gene. Log-based two-color scale is adjacent to the heatmap. Red denotes increased expression and green denotes decreased expression. Gene expression data is represented as Log2 normalized expression values. C-D. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19, respectively. E-H. Plasma cytokine <t>concentrations</t> <t>(IL6,</t> IP-10, SPP1 and TGFβ) in low, intermediate, and high-risk profile patients with COVID-19 at days 2, 6 and 13 post admission. The data is presented as an average of triplicate values ± SEM for each group. Two-way ANOVA test (GraphPad software) Tukey’s multiple comparisons were used; * p<0.05. I. Study design of 7-gene signature analysis by RT-qPCR in PBMCs from COVID-19 patients (Cohort 2). J. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS Up scores. Heatmap nomenclature is the same as in . K-L. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19 respectively in cohort two. The data is presented as an average of triplicated TUs values ± SEM for each group. * p<0.05
Human/Cytokine/Chemokine/Growth Factor Panel A 48 Plex Premixed Magnetic Bead Multiplex Assay, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human/cytokine/chemokine/growth factor panel a 48-plex premixed magnetic bead multiplex assay/product/Merck KGaA
Average 90 stars, based on 1 article reviews
human/cytokine/chemokine/growth factor panel a 48-plex premixed magnetic bead multiplex assay - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


A . Study design of the 50-gene signature and cytokine analysis in COVID-19 patients (Cohort 1). B. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS. Every column represents a patient, and every row represents a gene. Log-based two-color scale is adjacent to the heatmap. Red denotes increased expression and green denotes decreased expression. Gene expression data is represented as Log2 normalized expression values. C-D. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19, respectively. E-H. Plasma cytokine concentrations (IL6, IP-10, SPP1 and TGFβ) in low, intermediate, and high-risk profile patients with COVID-19 at days 2, 6 and 13 post admission. The data is presented as an average of triplicate values ± SEM for each group. Two-way ANOVA test (GraphPad software) Tukey’s multiple comparisons were used; * p<0.05. I. Study design of 7-gene signature analysis by RT-qPCR in PBMCs from COVID-19 patients (Cohort 2). J. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS Up scores. Heatmap nomenclature is the same as in . K-L. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19 respectively in cohort two. The data is presented as an average of triplicated TUs values ± SEM for each group. * p<0.05

Journal: bioRxiv

Article Title: A 50-gene high-risk profile predictive of COVID-19 and Idiopathic Pulmonary Fibrosis mortality originates from a genomic imbalance in monocyte and T-cell subsets that reverses in survivors with post-COVID-19 Interstitial Lung Disease

doi: 10.1101/2023.10.22.563156

Figure Lengend Snippet: A . Study design of the 50-gene signature and cytokine analysis in COVID-19 patients (Cohort 1). B. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS. Every column represents a patient, and every row represents a gene. Log-based two-color scale is adjacent to the heatmap. Red denotes increased expression and green denotes decreased expression. Gene expression data is represented as Log2 normalized expression values. C-D. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19, respectively. E-H. Plasma cytokine concentrations (IL6, IP-10, SPP1 and TGFβ) in low, intermediate, and high-risk profile patients with COVID-19 at days 2, 6 and 13 post admission. The data is presented as an average of triplicate values ± SEM for each group. Two-way ANOVA test (GraphPad software) Tukey’s multiple comparisons were used; * p<0.05. I. Study design of 7-gene signature analysis by RT-qPCR in PBMCs from COVID-19 patients (Cohort 2). J. Heatmap of COVID-19 patients based on the 50-gene signature discriminates three risk groups (low, intermediate, and high) based on SAMS Up scores. Heatmap nomenclature is the same as in . K-L. Time to death and time to discharge by day 60 in hospitalized patients with COVID-19 respectively in cohort two. The data is presented as an average of triplicated TUs values ± SEM for each group. * p<0.05

Article Snippet: We measured cytokine concentrations of 121 plasma samples from COVID-19 patients from Cohort 1 using a customized, Bioplex 200 compatible, human cytokine panel including, IL6, IP10, SPP1 and TGFβ-1 (#FCSTM18-06, R&D Systems).

Techniques: Expressing, Software, Quantitative RT-PCR